Voskuilen, Charlotte S. and van Gennep, Erik J. and Einerhand, Sarah M. H. and Vegt, Erik and Donswijk, Maarten L. and Bruining, Annemarie and van der Poel, Henk G. and Horenblas, Simon and Hendricksen, Kees and van Rhijn, Bas W. G. and Mertens, Laura S. (2022) yyStaging F-18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Changes Treatment Recommendation in Invasive Bladder Cancer. EUROPEAN UROLOGY ONCOLOGY, 5 (3). pp. 366-369. ISSN , 2588-9311
Full text not available from this repository. (Request a copy)Abstract
Given the high risk of systemic relapse following initial therapy for muscle-invasive bladder cancer (MIBC), improved pretreatment staging is needed. We evaluated the incremental value of F-18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) after standard conventional staging, in the largest cohort of MIBC patients to date. This is a retrospective analysis of 711 consecutive patients with invasive urothelial bladder cancer who underwent staging contrast-enhanced CT (chest and abdomen) and FDG-PET/CT in a tertiary referral center between 2011 and 2020. We recorded the clinical stage before and after FDG-PET/ CT and treatment recommendation based on the stage before and after FDG-PET/ CT. Clinical stage changed after FDG-PET/CT in 184/711 (26%) patients. Consequently, the recommended treatment strategy based on imaging changed in 127/711 (18%) patients. In 65/711 (9.1%) patients, potential curative treatment changed to palliative treatment because of the detection of distant metastases by FDG-PET/CT. Fifty (7.0%) patients were selected for neoadjuvant/induction chemotherapy based on FDG-PET/CT. Moreover, FDG-PET/CT detected lesions suspicious for second primary tumors in 15%; a second primary malignancy was confirmed in 28/711 (3.9%), leading to treatment change in ten (1.4%) patients. Contrarily 57/711 (8.1%) had false positive secondary findings. In conclusion, FDG-PET/CT provides important incremental staging information, which potentially influences clinical management in 18% of MIBC patients, but leads to false positive results as well. Patient summary: In this report, we investigated the impact of F-18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) scanning on treatment of bladder cancer patients. We found that FDG-PET/CT potentially influences the treatment of almost one-fifth of patients. We therefore suggest performing FDG-PET/CT as part of bladder cancer staging. (c) 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | MANAGEMENT; PET/CT; Bladder cancer; Diagnostic imaging; Lymph node metastases; Fluorodeoxyglucose F18; Positron emission tomography and computed tomography; Transitional cell carcinoma; Urinary bladder neoplasms |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Urologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 26 Jan 2024 12:11 |
| Last Modified: | 26 Jan 2024 12:12 |
| URI: | https://pred.uni-regensburg.de/id/eprint/58193 |
Actions (login required)
 |
View Item |
